EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical Application of Umbilical Cord Mesenchymal Stem Cells Preserves β-cells in Type 1 Diabetes

Ashraf Al Madhoun iD, Lubaina Koti, Neus Carrió, Maher Atari, Fahd Al-Mulla

Stem Cells Translational Medicine · 2024

DOI: 10.1093/stcltm/szad077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stem Cells Translational Medicine, 2024. Verfasst von Ashraf Al Madhoun und 4 weiteren Autor:innen. Beteiligte Einrichtung: Genetics and Bioinformatics, Dasman Diabetes Institute, Dasman 15462, Kuwait. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Wharton Jelly, Mesenchymal Stem Cells. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Kuwait Foundation for Advancement of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 1 diabetes (T1D) is a chronic autoimmune disease associated with complications that reduce the quality of life of affected individuals and their families. The therapeutic options for T1D are limited to insulin therapy and islet transplantation; these options are not focused on preserving β-cell function and endogenous insulin. Despite the promising outcomes observed in current clinical trials involving allogeneic Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs) infusion for the management of T1D, the precise underlying mechanism of action remains to be elucidated. In this correspondence, we propose prospective mechanisms of action of WJ-MSCs that may be mediating their observed capability to preserve β-cell function and prevent T1D progression and provide recommendations for further investigations in clinical settings. We also highlight the efficacy of WJ-MSCs for therapeutic applications in comparison to other adult MSCs. Finally, we recommend the participation of muti-centers governed by international organizations to implement guidelines for the safe practice of cell therapy and patients’ welfare.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Wharton JellyMesenchymal Stem CellsAdultHumansQuality of LifeUmbilical CordInsulinCell DifferentiationCells, CulturedCell Proliferation

Stichwörter der Autor:innen

ProTransWJ-MSCWharton’s jellyallogeneicclinical trialsmechanism of action

Substanzen

Insulin

Autor:innen und Institutionen

  • Genetics and Bioinformatics, Dasman Diabetes Institute, Dasman 15462, Kuwait.
  • Department of Periodontology, Universitat Internacional de Catalunya (UIC), C/Josep Trueta s/n, Sant Cugat del Valles, 08195 Barcelona, Spain.
  • Biointelligent Technology Systems SL, C/Diputaccion 316, 3D, 08009 Barcelona, Spain.

ORCID-Profile: Ashraf Al Madhoun

Förderung

  • Kuwait Foundation for Advancement of Sciences

Zitieren

APA

Al Madhoun, A., Koti, L., Carrió, N., Atari, M., & Al-Mulla, F. (2024). Clinical Application of Umbilical Cord Mesenchymal Stem Cells Preserves β-cells in Type 1 Diabetes. Stem Cells Translational Medicine. https://doi.org/10.1093/stcltm/szad077

Vancouver

Al Madhoun A, Koti L, Carrió N, Atari M, Al-Mulla F. Clinical Application of Umbilical Cord Mesenchymal Stem Cells Preserves β-cells in Type 1 Diabetes. Stem Cells Translational Medicine. 2024. doi:10.1093/stcltm/szad077

BibTeX
@article{AlMadhoun2024,
  author = {Al Madhoun, Ashraf and Koti, Lubaina and Carrió, Neus and Atari, Maher and Al-Mulla, Fahd},
  title = {Clinical Application of Umbilical Cord Mesenchymal Stem Cells Preserves β-cells in Type 1 Diabetes},
  journal = {Stem Cells Translational Medicine},
  year = {2024},
  doi = {10.1093/stcltm/szad077}
}
Kostenlos starten →